低-中剂量糖皮质激素对新型冠状病毒肺炎患者病毒清除率的回顾性研究

Q4 Medicine
N. Qin, Cheng Ding, Yongtao Li, Hong Zhao, Jun Liu, Xuan Zhang, Yanfei Chen, Yong-zheng Guo, Liang Yu, H. Ju, Jingjing Tao, Ping Yi, Guan-jing Lang, Jun-wei Su, D. Shi, Wen-rui Wu, Xiaoxin Wu, Ling Yu, J. Sheng, Kaijin Xu
{"title":"低-中剂量糖皮质激素对新型冠状病毒肺炎患者病毒清除率的回顾性研究","authors":"N. Qin, Cheng Ding, Yongtao Li, Hong Zhao, Jun Liu, Xuan Zhang, Yanfei Chen, Yong-zheng Guo, Liang Yu, H. Ju, Jingjing Tao, Ping Yi, Guan-jing Lang, Jun-wei Su, D. Shi, Wen-rui Wu, Xiaoxin Wu, Ling Yu, J. Sheng, Kaijin Xu","doi":"10.3760/CMA.J.CN115673-20200225-00072","DOIUrl":null,"url":null,"abstract":"Objective@#To study the effect of low-to-moderate dose glucocorticoid therapy on viral clearance time in patients with COVID-19.@*Methods@#A total of 72 patients diagnosed with COVID-19 from January 19 to February 17, 2020 at the First Affiliated Hospital, School of Medicine, Zhejiang University were recruited. All patients received oral abidol and/or combined lopinavir/ritonavir, darunavir antiviral, and symptomatic supportive care. Among them, 51 patients received methylprednisolone (0.75-1.50 mg·kg-1·d-1) (glucocorticoid treatment group), and 21 patients who did not use glucocorticoid were the control group. The time of stable virologic conversion insputumand the time of radiologic recovery in lungsince onset were compared between the two groups and among the normal patients.The Kruskal-Wallis test or Fisher exact test was used to compare the difference between groups.@*Results@#The median ages of the glucocorticoid group and the control group were 52 [interquartile range (IQR):45, 62] years and 46 (IQR: 32, 56)years, and the differences were significant (P 0.05), and the difference was no statistically significant. The median times from onset to radiologic recovery were 13 (IQR: 11,15) days and 13 (IQR:12,17) days in the two groups, and there was no difference (P>0.05). In ordinary patients, the median timesfrom the onset tostable virologic conversion insputum were no difference (P>0.05), with 13 (IQR:11,18) days in the glucocorticoid group and 13 (IQR:12,15) days in the control group; The median times from onset to radiologic recovery in lungwere also no difference (P>0.05), with 12 (IQR: 10,15)days in the glucocorticoid group and 13 (IQR: 12,17) days inthe control group.@*Conclusions@#Low-to-moderate glucocorticoid treatment has no effect on the time of virus clearance in patients with different clinical types of COVID-19. The glucocorticoid is not recommended since no effectiveness on accelerating the improvement of radiologic recovery in lung has been observed.","PeriodicalId":52394,"journal":{"name":"中华临床感染病杂志","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":"{\"title\":\"Retrospective study of low-to-moderate dose glucocorticoids on viral clearance in patients with novel coronavirus pneumonia\",\"authors\":\"N. Qin, Cheng Ding, Yongtao Li, Hong Zhao, Jun Liu, Xuan Zhang, Yanfei Chen, Yong-zheng Guo, Liang Yu, H. Ju, Jingjing Tao, Ping Yi, Guan-jing Lang, Jun-wei Su, D. Shi, Wen-rui Wu, Xiaoxin Wu, Ling Yu, J. Sheng, Kaijin Xu\",\"doi\":\"10.3760/CMA.J.CN115673-20200225-00072\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective@#To study the effect of low-to-moderate dose glucocorticoid therapy on viral clearance time in patients with COVID-19.@*Methods@#A total of 72 patients diagnosed with COVID-19 from January 19 to February 17, 2020 at the First Affiliated Hospital, School of Medicine, Zhejiang University were recruited. All patients received oral abidol and/or combined lopinavir/ritonavir, darunavir antiviral, and symptomatic supportive care. Among them, 51 patients received methylprednisolone (0.75-1.50 mg·kg-1·d-1) (glucocorticoid treatment group), and 21 patients who did not use glucocorticoid were the control group. The time of stable virologic conversion insputumand the time of radiologic recovery in lungsince onset were compared between the two groups and among the normal patients.The Kruskal-Wallis test or Fisher exact test was used to compare the difference between groups.@*Results@#The median ages of the glucocorticoid group and the control group were 52 [interquartile range (IQR):45, 62] years and 46 (IQR: 32, 56)years, and the differences were significant (P 0.05), and the difference was no statistically significant. The median times from onset to radiologic recovery were 13 (IQR: 11,15) days and 13 (IQR:12,17) days in the two groups, and there was no difference (P>0.05). In ordinary patients, the median timesfrom the onset tostable virologic conversion insputum were no difference (P>0.05), with 13 (IQR:11,18) days in the glucocorticoid group and 13 (IQR:12,15) days in the control group; The median times from onset to radiologic recovery in lungwere also no difference (P>0.05), with 12 (IQR: 10,15)days in the glucocorticoid group and 13 (IQR: 12,17) days inthe control group.@*Conclusions@#Low-to-moderate glucocorticoid treatment has no effect on the time of virus clearance in patients with different clinical types of COVID-19. The glucocorticoid is not recommended since no effectiveness on accelerating the improvement of radiologic recovery in lung has been observed.\",\"PeriodicalId\":52394,\"journal\":{\"name\":\"中华临床感染病杂志\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华临床感染病杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.CN115673-20200225-00072\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华临床感染病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN115673-20200225-00072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 12

摘要

目的研究低-中剂量糖皮质激素治疗对新冠肺炎患者病毒清除时间的影响。方法招募浙江大学医学院第一附属医院2020年1月19日至2月17日诊断为新冠肺炎的72例患者。所有患者均接受口服阿比多尔和/或洛匹那韦/利托那韦联合用药、达芦那韦抗病毒治疗和症状支持治疗。其中,51例患者接受了甲基强的松龙(0.75-1.50mg·kg-1·d-1)(糖皮质激素治疗组),21例未使用糖皮质激素的患者为对照组。比较两组患者和正常患者的稳定病毒学转化时间和发病时放射学恢复时间。使用Kruskal-Wallis检验或Fisher精确检验来比较各组之间的差异@*结果糖皮质激素组和对照组的中位年龄分别为52岁和46岁,差异有统计学意义(P<0.05),差异无统计学意义。两组从发病到放射学恢复的中位时间分别为13天(IQR:11,15)和13天(IQ R:12,17),差异无统计学意义(P>0.05);肺从发病到放射学恢复的中位时间也没有差异(P>0.05),糖皮质激素组为12(IQR:10,15)天,对照组为13(IQR:12,17)天@*结论@#低-中糖皮质激素治疗对不同临床类型新冠肺炎患者的病毒清除时间无影响。不推荐使用糖皮质激素,因为尚未观察到糖皮质激素对加速肺部放射学恢复的改善有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Retrospective study of low-to-moderate dose glucocorticoids on viral clearance in patients with novel coronavirus pneumonia
Objective@#To study the effect of low-to-moderate dose glucocorticoid therapy on viral clearance time in patients with COVID-19.@*Methods@#A total of 72 patients diagnosed with COVID-19 from January 19 to February 17, 2020 at the First Affiliated Hospital, School of Medicine, Zhejiang University were recruited. All patients received oral abidol and/or combined lopinavir/ritonavir, darunavir antiviral, and symptomatic supportive care. Among them, 51 patients received methylprednisolone (0.75-1.50 mg·kg-1·d-1) (glucocorticoid treatment group), and 21 patients who did not use glucocorticoid were the control group. The time of stable virologic conversion insputumand the time of radiologic recovery in lungsince onset were compared between the two groups and among the normal patients.The Kruskal-Wallis test or Fisher exact test was used to compare the difference between groups.@*Results@#The median ages of the glucocorticoid group and the control group were 52 [interquartile range (IQR):45, 62] years and 46 (IQR: 32, 56)years, and the differences were significant (P 0.05), and the difference was no statistically significant. The median times from onset to radiologic recovery were 13 (IQR: 11,15) days and 13 (IQR:12,17) days in the two groups, and there was no difference (P>0.05). In ordinary patients, the median timesfrom the onset tostable virologic conversion insputum were no difference (P>0.05), with 13 (IQR:11,18) days in the glucocorticoid group and 13 (IQR:12,15) days in the control group; The median times from onset to radiologic recovery in lungwere also no difference (P>0.05), with 12 (IQR: 10,15)days in the glucocorticoid group and 13 (IQR: 12,17) days inthe control group.@*Conclusions@#Low-to-moderate glucocorticoid treatment has no effect on the time of virus clearance in patients with different clinical types of COVID-19. The glucocorticoid is not recommended since no effectiveness on accelerating the improvement of radiologic recovery in lung has been observed.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中华临床感染病杂志
中华临床感染病杂志 Medicine-Infectious Diseases
CiteScore
0.70
自引率
0.00%
发文量
1445
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信